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Edited by Veli-Pekka LehtoAbstract A thorough understanding of histone acetyltransfer-
ase CBP/p300-mediated regulation of gene expression and cell
growth is essential to identify mechanisms relevant to the devel-
opment of histone deacetylase (HDAC) inhibitor-based preven-
tive and therapeutic strategies. We found that knockdown of
CBP/p300 interacting coactivator with glutamic acid/aspartic
acid-rich tail 2 (CITED2) increased colon cancer cell invasive-
ness in vitro. Gene expression profiling revealed that CITED2
knockdown induced matrix metalloproteinase-13 (MMP-13)
gene expression in colon cancer cells. Butyrate, a naturally
occurring HDAC inhibitor, induced CITED2 expression and
downregulated MMP-13 expression in RKO cells. Additionally,
ectopic expression of CITED2 arrested RKO cell growth. Thus,
CITED2 regulates colon cancer invasion and might be a target
for HDAC inhibitor-based intervention of colon cancer.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Colon cancer is the second leading cause of cancer death in
the United States. Colorectal cancer commonly metastasizes to
the liver [1], and as with most cancers, it is the metastasis that
is mainly responsible for high mortality rates. Thus, elucida-
tion of the mechanisms responsible for initiation, progression
and eventually metastasis of colon cancer metastases is re-
quired for the ultimate control of this disease. Evolution of
the metastatic phenotype requires enhanced cell invasiveness
to enable the tumor cell to separate from the primary site
and successfully establish a metastatic colony [2]. Unlike the
molecular events described for the pathogenesis of primary co-
lon tumors, the genes and pathways responsible for metastasis
in these tumors have not been well characterized.
Aberrant gene expression due to epigenetic changes has been
postulated to be a driving force underlying tumor progression,Abbreviations: CITED2, CBP/p300 interacting coactivator with glu-
tamic acid/aspartic acid-rich tail 2; MMP, matrix metalloproteinase;
HDAC, histone deacetylase
*Corresponding author. Address: Department of Internal Medicine,
University of Michigan, Ann Arbor, MI 48109-2200, USA. Fax: +1
734 763 4686.
E-mail address: merchanj@umich.edu (J.L. Merchant).
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.11.072and histone deacetylase (HDAC) and DNA methyltransferase
inhibitors-based epigenetic therapy has emerged as a reliable
approach for the intervention of cancer [3]. Functional CBP/
p300 is critical for transcriptional regulation of gene expression
and control of cell growth [4,5]. CBP/p300 loss-of-function is
associated with a variety of malignant cancers, including colon
cancer [6–8]. In the human colon cancer cell line HCT116,
p300 deletion leads to aggressive ‘‘cancer’’ phenotypes, includ-
ing increased migration and invasion in vitro [9].
CBP/p300 interacting coactivator with glutamic acid/aspar-
tic acid-rich tail 2 (CITED2) is a bifunctional protein that
belongs to a family of transcriptional cofactors that is charac-
terized by a conserved ED-rich domain at the C-terminus. A
functional motif (LPXL) within this domain is necessary and
sufficient for binding to the first cysteine–histidine-rich region
of CBP/p300 [10]. Initially described as a corepressor of hypox-
ia-inducing factor 1a (HIF1a) by competing for CBP/p300
binding [11], CITED2 also functions as a coactivator of activa-
tor protein 2 (AP-2) [12], PPARa and PPARc [13], and LIM-
homeodomain protein Lhx2 [14] by recruiting CBP/p300. Loss
of CITED2 in mice results in embryonic lethality – a conse-
quence of multiple developmental defects [15,16]. Ectopic
expression of melanocyte-specific gene related gene (MRG1),
an alternatively spliced isoform of CITED2, results in onco-
genic transformation in rat fibroblasts [17]. However, it is
not clear if CITED2 functions as a tumor-promoter or sup-
pressor. A recent study showed that knockdown of CITED2
in the breast cancer cell line MDA-MB-231 attenuates
TGFb1-mediated upregulation of matrix metalloproteinase-9
(MMP-9) and cell invasiveness in vitro [18]. This study raised
the possibility that CITED2 affects tumorigenesis by modulat-
ing tumor invasion rather than proliferation. Using CITED2
specific small hairpin (sh) RNA to knockdown CITED2
expression in human colon cancer cells, we observed that CI-
TED2 knockdown induced changes in cell morphology, con-
comitant with increased cancer cell invasiveness in vitro. Our
results suggest a pivotal role for CITED2 in colon cancer cell
growth regulation and may have important implications in tar-
geting CITED2 for nutrition-based chemoprevention and
chemotherapy for colon cancer.2. Materials and methods
2.1. Reagents
Monoclonal antibody against p21waf1 and rabbit polyclonal anti-
body against HDAC1 were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA); rabbit polyclonal antibody against acetyl-H2Ablished by Elsevier B.V. All rights reserved.
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anti-CITED2 (JA22) was obtained from Novus Biologicals (Littleton,
CO); and mouse monoclonal anti-b-catenin was obtained from BD
Biosciences Pharmingen. A control scrambled siRNA was obtained
from Ambion (Austin, TX).2.2. Plasmids
The pMK17, which contains 598 bp of human CITED2 proximal
promoter, was kindly provided by Dr. Shoumo Bhattacharya (Univer-
sity of Oxford). The plko1 lentiviral vector or plko1-shCITED2 which
expresses shRNA targeting the human CITED2 cDNA coding region
from +428 to +448 nt (BC004377) were obtained from the Open Bio-
systems (Huntsville, AL). The lentiviruses were produced at the Uni-
versity of Michigan Vector Core. The pOBT7-CITED2, which
contains the full-length human CITED2 cDNA was purchased from
the Origene (Rockville, MD). To generate HA-tagged CITED2 expres-
sion vector, the following primers were used to amplify full-length
CITED2 cDNA using the pOBT7-CITED2 as the template. Forward:
5 0-CCGACAAGCTTGCAGACCATATGATGGCAATGAACC-3 0;
backward: 5 0-TTAAGCGTAATCTGGAACATCGTATGGGTAA-
CAGCTCACTCTGCTGGGC-3 0. The PCR fragments were digested
with Hind III and inserted into the pCMV10 vector and verified by
sequencing. The expression of HA-CITED2 was verified by immuno-
blots.2.3. Cell culture
The human colon cancer cell line RKO was purchased from the
ATCC (Manassas, VA) and cultured in minimum essential medium
with 10% fetal bovine serum. To generate CITED2 knockdown stable
cell line, RKO cells were transduced with lentiviral empty vector or CI-
TED2 shRNA expressing vector and selected with puromycin at
0.1 lg/ml for 3–4 weeks. The pools of puromycin-resistant cells were
used for further analyses. To generate stable cell line that expresses
HA-tagged CITED2, cells were transfected with pCMV10 vector or
pCMV10-HA-CITED2 vector and selected with G418 at 0.5 mg/ml
for 3 weeks. The pools of G418-resistant cells were used for further
analyses.2.4. Reporter assay
Cells cultured in 48-well plates were transfected with human CI-
TED2 reporter pMK17 using FUGENE 6 (Roche). The cells were
treated with 2.5 mM sodium butyrate for 20 h prior to performing
luciferase reporter assays that were normalized to protein [19]. Lucifer-
ase assay was performed on Perkin–Elmer VICTOR3 1420 Multilabel
Counter using the Luciferase Reporter Assay System (Promega).2.5. Small interfering RNA
RNA interference experiments with small interfering RNA (siRNA)
were carried out as described before [20]. The region of CITED2
cDNA targeted for siRNA was: +519 5 0-AAGGTTTAACAACTCC-
CAGTT-30. A scrambled siRNA (Ambion) was used as control.
siRNAs were transfected into cells with Oligofectamine (Invitrogen).2.6. RNA isolation and RT-PCR analysis
Total RNA was isolated from cells using RNeasy mini kit (Qiagen)
following the manufacturers protocol. First-strand cDNA synthesis
was performed using the SuperScript III First-strand Synthesis Sys-
tem (Invitrogen). The sequences of primers and amplification condi-
tions are available upon request.
2.7. Matrigel invasion assay
Matrigel invasion assays were performed using BD Matrigel Inva-
sion Chamber (6-well plates, 8 lm pore size, BD Biosciences). Cells
were first cultured in serum free medium for 20–24 h, then collected
and resuspended in medium with 0.1% BSA at a density of
2.5 · 105 cells/ml. Culture medium with 10% FBS was added to the
lower chamber and 500 ll of the resuspended cells were added onto
the top of the Matrigel. Forty hours later, the non-invaded cells and
Matrigel on the topside of the transwell were scrapped off with cotton
swab. Cells on the lower surface of the membrane were fixed with
methanol, stained with haematoxylin and eosin (H&E) and viewed
with Olympus BX60 microscope using SPOT software.2.8. MMP-13 activity assay
Cells were seeded in 12-well plates at a density of 2 · 105/well.
Twelve hours later, cells were washed with PBS and incubated in
0.5 mL serum-free medium for another 24 h. The conditional medium
was collected, centrifuged at 10000 rpm for 5 min; and 25 ll of the
supernatant was used to detect MMP-13 activity using the SensoLyte
Plus 520 MMP-13 Assay Kit (AnaSpec, San Jose, CA) following the
manufacturers instruction. The fluorescence signal was measured by
VICTOR3 Multilabel Counter (Perkin–Elmer) with a filter set of exci-
tation/emission = 495 nm/535 nm.2.9. Confocal microscopy
Cells were fixed in 3.7% formaldehyde solution for 10 min, treated
with 0.1% Triton X-100 for 5 min, and incubated with Alexa fluor
488 phalloidin (Molecular Probes, Eugene, OR) for 30 min at room
temperature. The cells were mounted and examined with a confocal
microscope (Olympus FV-500) at the University of Michigan Micros-
copy & Image Analysis Lab.3. Results and discussion
3.1. CITED2 knockdown induced morphological changes in
colon cancer cells
To explore the functions of CITED2 in colonic cells, we used
CITED2-specific shRNA to knockdown its expression in the
colon cancer cell line RKO. As shown in Fig. 1A and B, both
CITED2 mRNA and protein levels were significantly reduced
by CITED2 shRNA. The expression of CITED4 was not af-
fected (Fig. 1A), which validated the specificity of CITED2
shRNA. Cells with reduced CITED2 expression induced a flat-
tened morphology compared to the control cells (Fig. 1C).
Notably, a flattened appearance is also a feature of CITED2
(/) mouse fibroblasts [21]. To determine whether the mor-
phological changes were associated with alterations in the actin
cytoskeleton, the cells were stained with phalloidin. Phalloidin
staining revealed cytoskeleton reorganization in CITED2
knockdown RKO cells (Fig. 1D).3.2. CITED2 knockdown increased colon cancer cell
invasiveness in vitro
Actin reorganization is normally associated with changes in
cancer cell migration and invasion [22]. Therefore, we assessed
whether the morphological changes in CITED2 knockdown
cells were accompanied by changes in cell migration and inva-
sion in vitro. Wound healing assays showed that CITED2
knockdown had no affect on cell migration (data not shown).
However, the Boyden chamber invasion assay demonstrated
that the CITED2 knockdown significantly increased the inva-
siveness of RKO cells (Fig. 2). Given the importance ofWnt sig-
naling in colon cancer progression, we examined whether the
phenotypic changes in CITED2 knockdown cells were accom-
panied by alterations in the Wnt/b-catenin pathway. As shown
inFig. 3A, reduced levels of CITED2 had no significant affect on
the subcellular localization of b-catenin in RKO cells, nor the
expression of b-catenin and TCF (Fig. 3B). The lack of induc-
tion of the b-catenin pathway correlates with the lack of induc-
tion of downstream targets, e.g., cyclin D1 and c-myc (Fig. 3B).
Therefore, reduced levels of CITED2 induced phenotypic
changes that were independent of the b-catenin/TCF pathway.3.3. CITED2 knockdown upregulated MMP-13 expression
To identify key genes involved in the phenotypic changes in
CITED2 knockdown of the RKO cells, we performed DNA
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Fig. 2. CITED2 knockdown increased cell invasive capacity. (A) RKO
cells were first cultured in serum free medium for 20–24 h, then
collected and resuspended in medium with 0.1% BSA. Culture medium
with 10% FBS was added to the lower chamber of BD Matrigel
Invasion Chamber and the resuspended cells were added onto the top
of the Matrigel. Forty hours later, cells on the lower surface of the
membrane were fixed with methanol, stained with H&E and viewed
with microscope (magnification: 20·). Representative images from
three independent experiments are shown. (B) Cells on the lower
surface of the membrane were counted under a microscope. Data
shown are means ± S.E.M. for numbers of cells from three indepen-
dent experiments, and 10 fields were counted from each experiment.
Fig. 1. CITED2 knockdown induced morphological changes in RKO
cells. (A) RKO cells were transduced with plko1 empty lentiviral vector
or plko1-shCITED2, and selected with puromycin for 3 weeks. The
pools of puromycin-resistant cells were used for total RNA isolation
and RT-PCR analyses. (B) Whole cell extracts were prepared and
mouse anti-CITED2 (Novus Biologicals) and anti-GAPDH (Chem-
icon) antibodies were used for immunoblotting (IB). (C) Phase
contrast microscopy of live cells (magnification: 200·). (D) Cells were
stained with Alexa fluor 488 phalloidin (Molecular Probes) and
examined with confocal microscope (magnification: 400·).
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U133 Plus 2.0 Array. A total of 739 genes were differentially
regulated by a factor of 2.5-fold when CITED2 levels were de-
creased: 235 genes were upregulated and 504 genes were down-
regulated. Among the differentially regulated genes, MMP-13
was significantly upregulated in CITED2 knockdown cells
(4-fold), suggesting that this metalloproteinase was specifically
inhibited by CITED2. To determine whether the upregulation
of MMP-13 in CITED2 knockdown cells is an early response
of CITED2 knockdown or the consequence of chronic cellular
physiological changes, we performed transient siRNA trans-
fection experiments. Total RNA was isolated 20 h after siRNA
transfection, and RT-PCR was performed to survey the
expression of MMP1–3 and 7–16. Of the MMPs detected in
RKO cells, MMP-13 was significantly upregulated by CITED2
silencing (Fig. 4A). Notably, it has been reported that CITED2
mediates flow shear regulated expression of MMP-1 and
MMP-13 in human chondrocytes [18]. However, MMP-9was essentially undetectable in RKO cells and the levels were
not significantly induced in contrast to what has been reported
for this target of CITED2 in human breast cancer cell line
MDA-MB-231 [18]. Thus regulation of MMP-9 by CITED2
may be cell dependent. Enzyme-linked immunosorbent assay
for MMP-13 confirmed that CITED2 knockdown significantly
increased the cell levels of MMP-13 protein (data not shown).
Accordingly, MMP-13 activity was also significantly increased
in the medium of CITED2 knockdown cells (Fig. 4B). Previ-
ous studies have established a critical role for MMPs in colon
cancer invasion and metastasis [23]. In particular, elevated
MMP-13 expression is associated with poor prognosis in colon
cancer [24]. We therefore assessed whether neutralizing
MMP13 activity with its antibody blocked RKO cell invasion
in vitro. Incubation of cells with the anti-MMP-13 monoclonal
antibody VIIA2 (Calbiochem) reduced the invasive capacity of
cells expressing reduced levels of CITED2 by 25% (data not
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Fig. 3. CITED2 knockdown does not affect the b-catenin pathway. (A) Whole cell extract (WCE), cytoplasmic (Cyto) and nuclear (Nucl) fractions of
RKO cells were prepared for immunoblotting. Rabbit anti-HDAC1 (Santa Cruz Biotechnology) and mouse anti-b-catenin (BD Biosciences) were
used for immunoblotting. HDAC1 was used as a marker for the nuclear fraction, and GAPDH was used as a marker for the cytoplasmic fraction. (B)
Total RNA was isolated from cells for RT-PCR as described above.
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cells (e.g., cytoskeletal reorganization) also contribute to the
altered invasiveness of these cells.
To investigate whether CITED2 commonly regulates MMP-
13 expression in colon cancer cell lines, we silenced CITED2
expression in SW480 colon cancer cells with siRNA. As shown
in Fig. 5A, CITED2-specific siRNA reduced CITED2 expres-
sion by 70% (Fig. 5A). Of the 11 MMPs detected in this cell
line, MMP-13 was most significantly up-regulated (Fig. 5A) as
observed with RKO cells (Fig. 4A). The expression of MMP-8,
-9, -11, and -15 was also slightly upregulated with the knock-
down of CITED2. Contrary to the slight upregulation of
MMP-1 in CITED2-knockdown RKO cells, MMP-1 was
downregulated in CITED2-knockdown SW480 cells
(Fig. 5A), suggesting the different genetic and epigenetic back-
ground of colon cancer cells might also contribute to CITED2
functions. To further determine whether CITED2 regulates
SW480 invasiveness, we generated CITED2-knockdown stable
cell line (Fig. 5B) and performed Matrigel invasion assay. Boy-
den chamber invasion assay demonstrated that CITED2-
knockdown significantly increased the invasiveness of SW480
cells (Fig. 5C). Together, our data strongly support the notion
that CITED2 regulates MMP-13 expression and invasiveness
in colon cancer cell lines.
3.4. Butyrate upregulated CITED2 expression and
downregulated MMP-13 expression in colon cancer cells
Numerous studies have shown that butyrate, a major dietary
fermentation product and potent HDAC inhibitor, inhibits co-
lon cancer invasion [25–27]. Research also suggests that MMPs
expression can be epigenetically dysregulated as a result of his-
tone hypoacetylation during tumor progression [28]. It is
known that butyrate inhibits the expression of MMP-9 in
colon cancer cells [27,29], and MMP-1 and MMP-13 in chon-
drocytes [30]. Thus, we tested whether butyrate regulated
MMP-13 and/or CITED2 expression in RKO cells. As shown
in Fig. 6A, butyrate upregulated CITED2 expression anddownregulated MMP-13 expression in RKO cells. Reporter
assays demonstrated strong activation of the CITED2 pro-
moter by butyrate (Fig. 6B). To explore whether there is a di-
rect link between CITED2 and MMP-13 expression in colon
cancer cells, we overexpressed HA-tagged CITED2 in RKO
and SW480 cells. RT-PCR confirmed the overexpression of
CITED2 in both cell lines. Ectopic expression of CITED2
was accompanied by downregulation of MMP-13 expression
(Fig. 6C). This observation was consistent with a previous
report that overexpression of CITED2 represses MMP-13
expression in human chondrocytes [18]. The expression of
MMP-1, -9 and other MMPs was not significantly affected by
CITED2 overexpression (data not shown). Thus, butyrate stim-
ulates CITED2 expression, and CITED2 expression is inversely
correlated with MMP-13 expression in colon cancer cells.
3.5. CITED2 arrested cell growth when overexpressed in colon
cancer cells
Having established that CITED2 expression is upregulated
during stimulation to repress cell growth (Fig. 6), we investi-
gated its biological activity by overexpressing it in RKO cells.
As transfection efficiency in RKO cells is low by conventional
transient transfection, the cells were transfected with an empty
vector (pCMV10) or HA-tagged CITED2 expression vector
(pCMV10/HA-CITED2) followed by G418 selection to enrich
the transfected cells. Using this approach, we observed a 2- to
3-fold increase of CITED2 mRNA in the enriched HA-CI-
TED2-expressing RKO cells (data not shown). Because an
anti-proliferative effect of CITED2 was apparent during the
selection of the ‘‘stable’’ populations, we analyzed cell-cycle
transition by flow cytometry. We found that ectopic expression
of CITED2 arrested RKO cell growth (Fig. 7A). Accordingly,
overexpression of CITED2 increased cyclin-dependent kinase
inhibitor p21waf1 expression and significantly enhanced buty-
rate-induced p21waf1 expression (Fig. 7B).
Among the CITEDs, CITED2 and CITED4 share some sim-
ilarities. Firstly, both CITED2 and CITED4 are transcrip-
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Fig. 4. CITED2 knockdown increased MMP-13 expression and
enzyme activity in RKO cells. (A) RKO cells were transfected with a
control siRNA (Ambion) or CITED2-specific siRNA. Twenty hours
after transfection, total RNA was isolated for RT-PCR. (B) Cells were
seeded in 12-well plates. Twelve hours later, cells were washed and
incubated in serum-free medium for another 24 h. The medium was
collected, centrifuged; and the supernatant was used to assay MMP-13
activity.
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Fig. 5. CITED2 knockdown increased MMP-13 expression and cell
invasiveness in SW480 cells. (A) SW480 cells were transfected with a
control siRNA (Ambion) or CITED2-specific siRNA. Twenty hours
after transfection, total RNA was isolated for RT-PCR. (B) SW480
cells were transduced with plko1 empty lentiviral vector or plko1-
shCITED2, and selected with puromycin for 3 weeks. The pools of
puromycin-resistant cells were used for RT-PCR (upper panels) and
Western blot (lower panels) analyses. (C) Matrigel invasion assays of
cells in (B) were performed as described in Fig. 2B. Twenty-four hours
after invasion, cells on the lower surface of the membrane were stained
with H and E and counted. Data shown are means ± S.E.M. of cells
from three independent experiments, and 10 fields were counted from
each experiment.
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CBP/p300 binding [31]. HIF1a responsive genes are involved
in many biological processes including angiogenesis, inva-C
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Fig. 6. Butyrate upregulated CITED2 expression and downregulated MMP
sodium butyrate for 16 h. Total RNA was isolated for RT-PCR. (B) RKO ce
butyrate for 20 h prior to luciferase reporter assays that were normalized to
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total RNA was isolated for RT-PCR analyses.sion/metastasis, cytoskeletal structure, and cell proliferation/
survival [32]. Secondly, both CITED2 and CITED4 also func-
tion as coactivators of transcription factor AP-2 by bridging
the interaction between AP-2 and CBP/p300 [12,33]. AP-2 isate
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C
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protein. Results are presented as means ± S.E.M. of three experiments.
MV10/HA-CITED2 (HA-C2). Two days later, cells were collected and
Fig. 7. Ectopic expression of CITED2 arrested RKO cells. (A) RKO
cells were transfected with pCMV10 vector or pCMV10/HA-CITED2
and selected with G418 at 0.5 mg/ml for 3 weeks. Cells were then
seeded in 12-well plates at a confluency of 25%. Forty hours later,
cells were collected for flow cytometry. Data shown are mean-
s ± S.E.M. of three repeats. *P < 0.05. (B) Cells were incubated with
2.5 mM sodium butyrate for up to 8 h. Western blot was performed.
L. Bai, J.L. Merchant / FEBS Letters 581 (2007) 5904–5910 5909important to epithelial cells and has been implicated in activi-
ties such as mediation of growth arrest through activation of
p21waf1 [34], maintenance of homotypic cell–cell adhesion
through activation of E-cadherin [35] and promotion of apop-
tosis [36]. Fox et al. [31] documented that breast cancer devel-
opment is characterized by either nuclear loss or cytoplasmic
translocation of CITED4, with subsequent loss of HIF1a tran-
scriptional antagonist activity. The striking similarities be-
tween CITED2 and CITED4 suggest a role for CITED2 in
human tumorigenesis. A recent study showed that knockdown
of CITED2 in breast cancer cell line MDA-MB-231 diminishes
stimulation of MMP-9 and cell invasiveness by TGFb1 in vitro
[18]. However, our study suggests that CITED2 might act as a
repressor of colon cancer progression. In fact, we found that
CITED2 suppressed colon cancer cell growth when overex-
pressed (data not shown). Thus, it may prove fruitful to study
the function of CITED2 in other types of cancers and deter-
mine whether the state of CITED2 (e.g., expression and sub-
cellular localization) changes during tumor progression.
Collectively, our study provides a strong rationale for further
exploring the roles of CITED2 in colon cancer progression
and the possibilities of targeting CITED2 for chemoprevention
and chemotherapy for colon cancer.
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